Literature DB >> 2161432

Involvement of cyclic adenosine monophosphate in the interleukin 4 inhibitory effect on interleukin 2-induced lymphokine-activated killer generation.

J Y Blay1, D Branellec, E Robinet, B Dugas, F Gay, S Chouaïb.   

Abstract

In previous studies, IL-4 has been reported to interfere with IL-2-driven generation of lymphokine-activated killer (LAK) activity. In this investigation, we have demonstrated that IL-4 inhibited the IL-2-induced differentiation of large granular lymphocytes (LGL) into LAK effectors by a mechanism involving, at least in part, an increase in LGL intracellular cAMP levels. In contrast, with its capacity to induce cAMP accumulation in resting LGL, IL-4 had a very negligible effect on LAK activity induction, and cAMP levels increase in LGL that had been preincubated with IL-2. Furthermore, the inhibitory effect of IL-4 on LAK activity generation also correlated with a marked decrease in N-CBZ-L-lysine thiobenzylester esterase activity, with an inhibition of tumor necrosis factor (TNF) mRNA expression and TNF production by IL-2-stimulated LGL. These results strongly suggest that complex signaling processes could be ascribed to the dual activities of cytokines and their interplay in LAK promotion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161432      PMCID: PMC296658          DOI: 10.1172/JCI114653

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester.

Authors:  T Nishimura; S J Burakoff; S H Herrmann
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

2.  Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2.

Authors:  P H Hart; G F Vitti; D R Burgess; G A Whitty; D S Piccoli; J A Hamilton
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  IL-2 induces expression of serine protease enzymes and genes in natural killer and nonspecific T killer cells.

Authors:  C L Manyak; G P Norton; C G Lobe; R C Bleackley; H K Gershenfeld; I L Weissman; V Kumar; N H Sigal; G C Koo
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

4.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

Review 5.  The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response.

Authors:  G M Kammer
Journal:  Immunol Today       Date:  1988 Jul-Aug

6.  Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2.

Authors:  S Chouaib; J Bertoglio; J Y Blay; C Marchiol-Fournigault; D Fradelizi
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

7.  cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete point in early G1.

Authors:  K W Johnson; B H Davis; K A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

8.  Human lymphocytic metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin.

Authors:  J W Smith; A L Steiner; C W Parker
Journal:  J Clin Invest       Date:  1971-02       Impact factor: 14.808

9.  Functional interactions of IL2 and TNF in the differentiation of LGL into LAK effectors.

Authors:  J Y Blay; J Bertoglio; D Fradelizi; S Chouaib
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

10.  IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.

Authors:  Y Kawakami; M C Custer; S A Rosenberg; M T Lotze
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

View more
  3 in total

1.  Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.

Authors:  A D Roth; S Dupuis; P Alberto
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

3.  Interleukin-4 suppression of monocyte tumour necrosis factor-alpha production. Dependence on protein synthesis but not on cyclic AMP production.

Authors:  P H Hart; C A Jones; J J Finlay-Jones
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.